The stock market went up on Tuesday to clinch another record high for S&P500 and NASDAQ. This was propelled by President Donald Trump’s announcement on U.S.-Vietnam trade deal. The deal includes a 20% tariff on imports from Vietnam.
However, the optimism brought about by the deal was partly offset by signs of continued labor market slowdown.
Overall, S&P 500 rose 0.5% to 6,227, while NASDAQ increased 0.9% to 20,393.
Tweet of the Day
Good analysis on Oscar Health $OSCR https://t.co/L4xZSulIBu
— David Sharek (@GrowthStockGuy) July 2, 2025
Chart of the Day
Here is the one-year chart of Hims & Hers Health (HIMS) as of May 27, 2025, when the stock was at $53.
Hims & Hers Health’s profit tripled last quarter as revenue more than doubled. Profits grew 300% as revenue spiked 111%. Subscribers grew 38% to 2.4 million.
The company also launched the branded Wegovy through its partnership with Novo Nordisk Growth and has added it to its weight loss lineup of oral kits, liraglutide, and personalized semaglutide. The weight loss segment became one of its biggest segments and drove average monthly revenue per user to $84, up more than 50% from last year.
Most recently, the Hers side of the company launched hair loss gummies with Minolixil and biotin, a vitamin for healthy skin, hair and nails. Hims and Hers Health has been hot recently as the stock has gained investors’ attention. However, the move seems too-far, too-fast.
HIMS is part of our Growth Portfolio and Aggressive Growth Portfolio.
